Associations between purine metabolites and clinical symptoms in schizophrenia

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Yao, Jeffrey K ^a,b,c   Condray, Ruth ^a,b   Dougherty, George G ^a,b   Keshavan, Matcheri S ^b,d   Montrose, Debra M ^b   Matson, Wayne R ^a   McEvoy, Joseph ^e   Kaddurah Daouk, Rima ^e   Reddy, Ravinder D ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GUANINE; GUANOSINE; NEUROLEPTIC AGENT; PURINE DERIVATIVE; URIC ACID; XANTHOSINE;

ADULT; ARTICLE; CATABOLISM; CLINICAL ARTICLE; CLINICAL FEATURE; COULOMETRY; DISEASE ASSOCIATION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; METABOLIC BALANCE; METABOLITE; NEUROLOGIC EXAMINATION; PATIENT ASSESSMENT; PREDICTION; PURINE METABOLISM; SCHIZOPHRENIA; SYMPTOM; THOUGHT DISORDER; TREATMENT DURATION;

ADOLESCENT; ADULT; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ELECTROCHEMICAL TECHNIQUES; ELECTRODES; FEMALE; HOMEOSTASIS; HUMANS; MALE; PURINES; SCHIZOPHRENIA; YOUNG ADULT;

EID: 84865053122     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0042165     Document Type: Article

References (44)

1. Cadet JL, Lohr JB, ((1987)) Free radicals and the developmental pathology of schizophrenic burnout. Integrative Psychiatry 5:: 40--48.
2. Do KQ, Cabungcal JH, Frank A, Steullet P, Cuenod M, ((2009)) Redox dysregulation, neurodevelopment, and schizophrenia. Curr Opin Neurobiol 19:: 220--230.
3. Lohr JB, ((1991)) Oxygen radicals and neuropsychiatric illness: Some speculations. Arch Gen Psychiatry 48:: 1097--1106.
4. Matsuzawa D, Hashimoto K, Hashimoto T, Shimizu E, Watanabe H, et al. ((2009)) Association study between the genetic polymorphisms of glutathione-related enzymes and schizophrenia in a Japanese population. Am J Med Genet B Neuropsychiatr Genet 150B:: 86--94.
5. Reddy R, Yao JK, ((1996)) Free radical pathology in schizophrenia: A review. Prostaglandins Leukot Essent Fatty Acids 55:: 33--43.
6. Yao JK, Keshavan MS, ((2011)) Antioxidants, Redox Signaling, and Pathophysiology in Schizophrenia: An Integrative View. Antioxidants & Redox Signaling 15:: 2011--2035.
7. Yao JK, Leonard S, Reddy RD, ((2006)) Altered glutathione redox state in schizophrenia. Disease Markers 22:: 83--93.
8. Yao JK, Dougherty GG, Reddy RD, Keshavan MS, Montrose DM, et al. ((2010)) Homeostatic imbalance of purine catabolism in first-episode neuroleptic-naïve patients with schizophrenia. PLoS One 5:: e9508 doi:10.1371/journal.pone.0009508.
9. Kristal BS, Vigneau-Callahan KE, Moskowitz AJ, Matson WR, ((1999)) Purine Catabolism: Links to Mitochondrial Respiration and Antioxidant Defenses? Arch Biochem Biophys 370:: 22--33.
10. Endicott J, Spitzer RL, Fleiss JL, Cohen J, ((1976)) The Global Assessment Scale: a procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry 33:: 766--771.
11. Overall JE, Gorham DR, ((1962)) The Brief Psychiatric Rating Scale. Psychol Rep 10:: 779--812.
12. Andreasen NC (1983) Scale for the Assessment of Negative Symptoms. Iowa City: University of Iowa Press.
13. Buchanan RW, Heinrichs DW, ((1989)) The Neurological Evaluation Scale (NES): A structured instrument for the assessment of neurological signs in schizophrenia. Psychiatry Research 27:: 335--350.
14. Bogdanov M, Matson WR, Wang L, Matson T, Saunders-Pullman R, et al. ((2008)) Metabolomic profiling to develop blood biomarkers for Parkinson's disease. Brain 131:: 389--396.
15. Yao JK, Dougherty GG, Reddy RD, Keshavan MS, Montrose DM, et al. ((2010)) Altered interactions of tryptophan metabolites in first-episode neuroleptic-naïve patients with schizophrenia. Mol Psychiatry 15:: 938--953.
16. Kristal BS, Shurubor YI, Kaddurah-Daouk R, Matson WR, ((2007)) High-performance liquid chromatography separations coupled with coulometric electrode array detectors: a unique approach to metabolomics. Methods Mol Biol 358:: 159--174.
17. Shi H, Vigneau-Callahan KE, Matson WR, Kristal BS, ((2002)) Attention to relative response across sequential electrodes improves quantitation of coulometric array. Anal Biochem 302:: 239--245.
18. Schiavo S, Ebbel E, Sharma S, Matson W, Kristal BS, et al. ((2008)) Metabolite identification using a nanoelectrospray LC-EC-array integrated system. Anal Chem 80:: 5912--5923.
19. Bruning JL, Kintz BL (1987) Computational handbook of statistics (3rd ed.). Illinois: Scott, Foresman and Company.
20. Sanders RD, Schuepbach D, Goldstein G, Haas GL, Sweeney JA, et al. ((2004)) Relationships between cognitive and neurological performance in neuroleptic-naïve psychosis. J Neuropsychiat Clin Neurosci 16:: 480--487.
21. Becker BF, ((1993)) Towards the physiological function of uric acid. J Free Radic Biol Med 14:: 615--631.
22. Strazzullo P, Puig JG, ((2007)) Uric acid and oxidative stress: relative impact on cardiovascular risk? Nutr Metab Cardiovasc Dis 17:: 409--414.
23. Hyden MR, Tyagi SC, ((2004)) Uric acid: a new look at an old risk marker for cardiovascular disease, metabolic syndrome, and type 2 diabetes mellitus: the urate redox shuttle. Nutr Metab (Lond) 1:: 10.
24. Linden J, Rosin DL (2006) Purinergic system. In: Siegel GJ, Albers RW, Brady ST, Price DL, editors. Basic Neurochemistry, Molecular, Cellular and Medical Aspects, 7th edition. Boston: Elsevier. pp. 303-316.
25. Yao JK, Reddy R, van Kammen DP, ((1998)) Reduced level of plasma antioxidant uric acid in schizophrenia. Psychiatry Res 80:: 29--39.
26. Reddy RD, Keshavan MS, Yao JK, ((2003)) Reduced plasma antioxidants in first-episode patients with schizophrenia. Schizophr Res 62:: 205--212.
27. Kutzing MK, Firestein BL, ((2007)) Altered uric acid levels and disease states. J Pharm Exp Therapeutics 324:: 1--7.
28. Gupta S, Andreasen NC, Arndt S, Flaum M, Schultz SK, et al. ((1995)) Neurological soft signs in neuroleptic-naïve and neuroleptic-treated schizophrenic patients and in normal comparison subjects. Am J Psychiatry 152:: 191--196.
29. Keshavan MS, Sanders RD, Sweeney JA, Diwadkar VA, Goldstein G, et al. ((2003)) Diagnostic specificity and neuroanatomical validity of neurological abnormalities in first-episode psychoses. Am J Psychiatry 160:: 1298--1304.
30. Mohr F, Hubmann W, Albus M, Franz U, Hecht S, et al. ((2003)) Neurological soft signs and neuropsychological performance in patients with first episode schizophrenia. Psychiatry Res 121:: 21--30.
31. Rubin P, Vorstrup S, Hemmingsen R, Andersen HS, Bendsen BB, et al. ((1994)) Neurological abnormalities in patients with schizophrenia or schizophreniform disorder at first admission to hospital: correlations with computerized tomography and regional cerebral blood flow findings. Acta Psychiatr Scand 90:: 385--390.
32. Sanders RD, Keshavan MS, Forman SD, Pieri JN, McLaughlin N, et al. ((2000)) Factor structure of neurological examination abnormalities in unmedicated schizophrenia. Psychiatry Res 95:: 237--243.
33. Sanders RD, Joo YH, Almasy L, Wood J, Keshavan MS, et al. ((2006)) Are neurologic examination abnormalities heritable? A preliminary study. Schizophr Res 86:: 172--180.
34. Arango C, Bartko JJ, Gold JM, Buchanan RW, ((1999)) Prediction of neuropsychological performance by neurological signs in schizophrenia. Am J Psychiatry 156:: 1349--1357.
35. Stetten D Jr, Hearon JZ, ((1959)) Intellectual level measured by army classification battery and serum uric acid concentration. Science 129:: 1737.
36. Kasl SV, Brooks GW, Rodgers WL, ((1970)) Serum uric acid and cholesterol in achievement behavior and motivation: I. The relationship to ability, grades, test performance, and motivation. JAMA 213:: 1158--1164.
37. Kasl SV, Brooks GW, Rodgers WL, ((1970)) Serum uric acid and cholesterol in achievement behavior and motivation: II. The relationship to college attendance, extracurricular and social activities, and vocational aspirations. JAMA 213:: 1291--1299.
38. Barrera CM, Ruiz ZR, Dunlap WP, ((1988)) Uric acid: A participating factor in the symptoms of hyperactivity. Biol Psychiatry 24:: 344--347.
39. Álvarez B, Macarrón-Vicente J, ((2010)) Uric acid and evolution. Rheumatology 49:: 2010--2015.
40. de Lau LM, Koudstaal PJ, Hoffman A, Breteler MM, ((2005)) Serum uric acid levels and the risk of Parkinson disease. Annals Neurology 58:: 797--800.
41. Annanmaki T, Pessala-Driver A, Hokkanen L, Murros K, ((2008)) Uric acid associates with cognition in Parkinson's disease. Parkinsonism and Related Disorders 14:: 576--578.
42. Barrera CM, Hunter RE, Dunlap WP, ((1989)) Hyperuricemia and locomotor activity in developing rats. Pharmacol Biochem Behavior 33:: 367--369.
43. Nagamine T, ((2010)) Abnormal laboratory values during the acute and recovery phases in schizophrenic patients: a retrospective study. Neuropsychiatric Disease and Treatment 6:: 281--288.
44. Ishay JS, Paniry VA, ((1979)) Effects of caffeine and xanthines on hornets and bees. Psychopharmacology 65:: 299--309.